New immunosuppressive therapies in renal transplantation: Monoclonal antibodies

Journal of Nephrology

Volumn 18, Issue 5, 2005, Pages 529-536

  Buhaescu, Irina ^a   Segall, Liviu ^a   Goldsmith, David ^b   Covic, Adrian ^a  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Monoclonal antibodies; Renal transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EFALIZUMAB; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED 1 MONOCLONAL ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ODULIMOMAB; OKT 3; PREDNISONE; PRIXILIMAB; RAPAMYCIN; RITUXIMAB; T 10B9; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT REJECTION; ANTIGEN RECOGNITION; ASEPTIC MENINGITIS; CANCER; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG RESEARCH; DRUG SPECIFICITY; DRUG TOLERABILITY; DYSLIPIDEMIA; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; RECEPTOR BINDING; RECIPIENT; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; TRANSPLANTATION TOLERANCE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, CD4; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CD40 LIGAND; GLYCOPROTEINS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29244466112     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337-42.
2. Vincenti F. New monoclonal antibodies in renal transplantation. Minerva Urol Nefrol 2003; 55: 57-66.
3. Kahan BD, Rajagopalan PR, Hall M. For The United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999; 67: 276-84.
4. Nashan B, Light S, Hardie IR, Lin A, Johnson R. For The Daclizumab Double Therapy Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110-5.
5. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. For The Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-5.
6. Nashan B, Moore R, Amlot P. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193-8.
7. Vincenti F, Grinyó JM, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R. Can antibody prophylaxis allow sparing of other immunosuppressives. Transplant Proc 1999; 31: 1246-8.
8. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234-41.
9. Light JA, Sasaki TM, Ghasemian R, Barhyte DY, Fowlkes DL. Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. Clin Transplant 2002; 16 (suppl 7): S30-3.
10. Vincenti F, Ramos E, Bratstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282-7.
11. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomised trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-6.
12. Tran HT, Acharya AM, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H Jr, Kirkman RL, Milford EL. Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil and steroids. J Am Soc Nephrol 2000; 11: 1903-9.
13. Lebranchu Y, Bridoux F, Büchler M, Le Meur Y, Etienne I, Toupance O, Hurault de Ligny B, Touchard G, Moulin B, Le Pogamp P, Reigneau O, Guignard M, Rifle G. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48-56.
14. Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915-9.
15. Wright FH, Thacker LR, Peters TG. Improved results in high-immunologic risk renal allograft recipients using a daclizumab (Zenapax) versus traditional antilymphocyte therapy in member centers of the South Eastern Organ Procurement Foundation. Am J Transplant 2001; 1: 150. Abstract 60.
16. Brennan DC. A prospective, randomized, multicenter study of thymoglobulin compared with basiliximab for induction immunosuppression: preliminary results. Am J Transplant 2002; 2: 238. Abstract 398.
17. Kawai T, Sogawa H, Boskovic S, Abrahamian G, Smith RN, Wee SL, Andrews D, Nadazdin O, Koyama I, Sykes M, Winn HJ, Colvin RB, Sachs DH, Cosimi AB. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004; 4: 1391-8.
18. Kanmaz T, Fechner JJ Jr, Torrealba J, Kim HT, Dong Y, Oberley TD, Schultz JM, Bloom DD, Katayama M, Dar W, Markovits J, Schuler W, Hu H, Hamawy MM, Knechtle SJ. Monotherapy with the novel human anti-CD 154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model. Transplantation 2004; 77: 914-20.
19. Schuler W, Bigaud M, Brinkmann V, Di Padova F, Geisse S, Gram H, Hungerford V, Kleuser B, Kristofic C, Menninger K, Tees R, Wieczorek G, Wilt C, Wioland C, Zurini M. Efficacy and safety of ABI793, a novel human anti-human CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation. Transplantation 2004; 77: 717-26.
20. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K, Fechner JH Jr, Germond RL, Kampen RL, Patterson NB, Swanson SJ, Tadaki DK, TenHoor CN, White L, Knechtle SJ, Harlan DM. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primate. Nat Med 1999; 5: 686-93.
21. Koyama I, Kawai T, Andrews D, Boskovic S, Nadazdin O, Wee SL, Sogawa H, Wu DL, Smith RN, Colvin RB, Sachs DH, Cosimi AB. Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates. Transplantation 2004; 77: 460-2.
22. Meiser BM, Reiter C, Reichenspurner H, Uberfuhr P, Kreuzer E, Rieber EP, Riethmuller G, Reichart B. Chimeric monoclonal CD4 antibody: a novel immunosuppressant for clinical heart transplantation. Transplantation 1994; 58: 419-23.
23. Dantal J, Ninen E, Hourmant M, Boeffard F, Cantarovich D, Giral M, Wijdenes J, Soulillou JP, Le Mauff B. Anti-CD4 MoAb therapy in kidney transplantation: a pilot study in early prophylaxis of rejection. Transplantation 1996; 62: 1502-6.
24. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet 1999; 353: 1083-91.
25. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee SL, Rothlein R, Faanes R, Colvin RB. In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 1990; 144: 4604-12.
26. Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal O, Lins LE, Isoniemi H, Backman L, Persson N, Neumayer HH, Jorgensen PF, Spieker C, Hendry B, Nicholls A, Kirste G, Hasche G. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation. Transplantation 1999; 67: 729-36.
27. Kuypers DR, Vanrenterghem YF. Monoclonal antibodies in renal transplantation: old and new. Nephrol Dial Transplant 2004; 19: 297-300.
28. Hourmant M, Bedrossian J, Durand D, Lebranchu Y, Renoult E, Caudrelier P, Buffet R, Soulillou JP. A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation 1996; 62: 1565-70.
29. Vincenti F, Mendeze R, Rajagopalan PR. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. Am J Transplant 2001; 1 (suppl): S276. Abstract.
30. Brockmeyer C, Ulbrecht M, Schendel DJ, Weiss EH, Hillebrand G, Burkhardt K, Land W, Gokel MJ, Riethmuller G, Feucht HE. Distribution of cell adhesion molecules (ICAM1, VCAM1, ELAM1) in renal tissue during allograft rejection. Transplantation 1993; 55: 610-5.
31. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM1 and LFA1. Science 1992; 255: 1125-7.
32. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813-21.
33. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-81.
34. Hale G, Dyer MJ, Clark MR, Phillips JM, Marcus R, Riechmann L, Winter G, Waldmann H. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH 1H. Lancet 1988; 2; 1394-9.
35. Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. Result from a human renal allograft tolerance trial evaluating the humanized CD-52-specific monoclonal antibody alemtuzumab (CAMPATH 1H). Transplantation 2003; 76: 120-9.
36. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KG, Waldmann H. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-6.
37. Friend PJ, Hale G, Waldman H, Gore S, Thiru S, Joysey V, Evans DB, Calne RY. Campath-1M - prophylactic use after kidney transplantation. Transplantation 1989; 48: 248-53.
38. Knechtle SJ, Pirsch JD, H Fechner J Jr, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YF, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawy MM, Hu H, Bloom DD, Sollinger HW. Campath 1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722-30.
39. Rao V, Pirsch JD, Becker BN. Sirolimus monotherapy following Campath 1H induction. Transplant Proc 2003; 35 (suppl): S128-30.
40. Waid TH, Lucas BA, Thompson JS, McKeown JW, Brown S, Kryscio R, Skeeters LJ. Treatment of renal allograft rejection with T10B9.1A31 or OKT3. Transplantation 1997; 64: 274-81.
41. Becker YT, Becker BN, Pirsch JD. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
42. Sawada T, Fuchinoue S, Teraoka S. Successful A1 to O ABO incompatible kidney transplantation after a preconditioning regimen consisting of anti CD20 monoclonal infusion, splenectomy and double filtration plasmapheresis. Transplantation 2002; 74: 1207-10.
43. Tyden G, Kumlien G, Fehrman I. Successful ABO-incompatible kidney transplanatation without splenectomy using Ag-specific immunoadsorption and rituximab. Transplantation 2003; 76: 730-1.
44. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4: 1315-22.
45. Vieira CA, Agarwal A, Book BK, Sidner RA, Bearde CM, Gebel HM, Roggero AL, Fineberg NS, Taber T, Kraus MA, Pescovitz MD. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics and pharmacokinetics. Transplantation 2004; 27; 77: 542-8.
46. Matsubara E, Yakushijin Y, Nomura T, Iwamasa K, Narumi H, Sakai I, Yasukawa M, Fujita S, Hato T, Ohshima K, Uno M. Epstein Barr virus associated post-transplant lymphoproliferative disease after renal transplantation. Rinsho Ketsueki 2002; 43: 949-53.
47. Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, Barros V, Keitel E, Bittar AE, Ferrera des Santos A, Roithmann S. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transplant Int 2003; 16: 202-6.
48. Molnar I, Keung YK. Treatment of post-transplant lymphoproliferative disorder with rituximab and radiation in a patient with second renal allograft. Nephrol Dial Transplant 2001; 16: 2114-5.
49. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. Blood 2004; 104: 649-54.
50. Pascher A, Radke C, Dignass A, Schulz RJ, Veltzke-Schlieker W, Adler A, Sauer IM, Platz K, Klupp J, Volk HD, Neuhaus P, Mueller AR. Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. Transplantation 2003; 76: 615-8.
51. Afzali B, Shah S, Chowdhury P, O'Sullivan H, Taylor J, Goldsmith D. Low-dose mycophenolate mofetil is an effective and safe treatment to permit phased reduction in calcineurin inhibitors in chronic allograft nephropathy. Transplantation 2005; 79: 304-9.
52. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. New Engl J Med 1998; 338: 1813-21.
53. Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592-600.